Organization
Zheijang Cancer Hospital
1 abstract
Abstract
Results of a phase 1/2 study of MHB036C: A potential best-in-class TROP2 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in locally advanced or metastatic solid tumors.Org: Zheijang Cancer Hospital, Department of Oncology, the Second People's Hospital of Yibin, Nanyang First People's Hospital,